CFH and atypical hemolytic-uremic syndrome: aHUS is defined as complement-mediated TMA, in which dysregulation of the complement pathway (caused by a combination of genetic predispositions or anti-complement factor H (CFH) antibodies and triggers/underlying conditions) mediates the onset of TMA [3, 4].